breast cancer market1

8/8/2019 Breast Cancer Market1

1/9

The Cancer Market

Outlook to 2014

Competitive landscape, market size,

pipeline analysis and growth

opportunities

1995/2885/$3835

December 2009

Report Price

Publication date

H

EA

L

T

H

C

A

R

E

F o r a c l e a r e r m a r k e t p e r s p e c t i v e


2/9

The Cancer Market Outlook to 2014

Competitive landscape, market size, pipeline analysis and growth opportunities

Business Insights portfolio of healthcare reports is designed to help you make

well informed and timely business decisions. We understand the problems

facing today's pharmaceutical and healthcare executives when trying to drive

your business forward, and appreciate the importance of accurate, up-to-date,incisive product, market and company analysis. We help you to crystallize your

business decisions.

Business Insights reports are authored by independent experts and contain findings from dedicated primary

research. Our authors' leading positions secure them access to interview key executives and to establish which

issues will be of greatest strategic significance for the industry.

Our healthcare portfolio of reports can be used across a wide range of business functions to assess market

conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis,

market outlook, new business opportunities and strategic insight.

Pages 194

Figures 15

Tables 76

This report provides wide

coverage across the major

cancer markets, and provides

an analysis of marketed and

pipeline drugs. It also

analyzes the growth trends

and future market leaders,

forecasting revenues andepidemiology through the

period 2008-14...

In the current decade, oncology has been one of the most important growth

segments among the pharmaceutical markets with a major focus on targeted

agents. Most innovation in oncology over the past 10 years has been driven by

scientific advances, particularly in genomics, transcriptomics and proteomics. In

the current environment, the successful oncology players of the future will be

those that can anticipate protocol evolution and design the most relevant clinical

trials. In recent years, biotech companies have fuelled innovation in oncology

more than ever before. Partnering with biotech companies is a key (but

expensive) source of innovation for many pharma companies as approximately

75% of phase II, III and pre-registration innovative drugs are of biotech origin.

At $47.7bn, cancer is one of the largest and fastest growing markets in the

pharmaceutical industry. However, pricing risk remains the key investment

concern in oncology. The key concern, however, is not price erosion driven by

competitive forces, but price cuts imposed by payors irrespective of the fact that

such unilateral price cuts by payors have never occurred in any of the major

developed markets and would surely jeopardize the premise on which the entire

biopharmaceutical industry has been built.

This report provides coverage of over 95% of the total market for cancer products and enables the reader to

understand the issues behind the market-leading products of today and forecasts the market-leading products of

tomorrow. The report allows the reader to understand which pharmaceutical companies will be the dominant forces in

the cancer arena, and which products will be the strongest performers over the period 2009-14.

About Us

Report Overview


3/9



Key Findings

Use this report to...

In 2008, antineoplastic mAbs delivered huge sales

of $13.6bn with a market share of 28.6% of total

sales. The key antineoplastic mAbs which contributed to the

higher market share of this class in 2008 were MabThera(11.0%), Avastin (10.3%), Herceptin (9.7%) and Erbitux (3.4%).

Forecast sales of the total antineoplastics market are

estimated at $65.2bn in 2014.

Roche is the global market leader in cancer,

holding the highest market share of 29.2%

($14.0bn sales) in 2008 based on sales from (MabThera,

Avastin, Herceptin, Tarceva and Xeloda). Roches strength

in the cancer market has been bolstered by its acquisition of

Genentech and purchase of majority stakes in Chugai, whichhas provided additional breadth to its portfolio.

Eli Lillys acquisition of ImClone will increase the

formers flow of high-quality, innovative new

therapies. The transaction will immediately enable Eli Lilly to

offer physicians and their patients a complementary portfolio of

leading oncolytic agents and targeted therapies including Gemzar, Alimta and Erbitux.

Pfizers axitinib, Dendreons Provenge and GSK/Genmabs Arzerra are expected to be the top sellers

among late stage pipeline oncolytic agents.

Figure 4.7: Key drugs in late-stage

development or that have been recently

launched

More than $47.7bn worth of cancer drugs were soldglobally in 2008 with US making up for 39.1% of these

sales. The value of novel targeted therapies, their

combinations with chemotherapy, and the potential of

adjuvant therapy have demonstrated to improve survival

rates, notably in breast, lung and colon cancers

Develop insight into patient potential with

the reports coverage of major indications in the

cancer segment, the seven largest geographic

pharmaceutical markets and 10 largest

companies active in the cancer segment today

Quickly understand how recent events are

affecting the performance of major products,

and how their marketers are confronting

competitive changes in cancer marketplace

Gain up-to-date competitive intelligence

across the cancer indications and understand

the major issues affecting key

pharmaceutical/biotech players

Understand which indications have the

greatest potential to provide franchise

growth, and how pharmaceutical companies

are attempting to exploit these opportunities

Compare the franchises of toppharmaceutical marketers across major

indications, and understand how market share

of leading companies will change over the next

6 years

Use head-to head comparisons of the leading

cancer pipeline compounds to understand

which companies will have a presence among

key indications over the next 6 years


4/9



Key issues...

Discover...

FDA approves Cervarix for cervical cancer: In October 2009, FDA approved GSKs Cervarix for the

prevention of pre-cancerous lesions caused by human papillomavirus (HPV) type 16 & 18 in women aged

1025 years. Cervarixs inclusion in childrens vaccine program is a major step towards securing reimbursement.

Cervarix, expected to launch by the end of 2009, faces direct competition from Mercks Gardasil and will help toreduce the incidence of cervical cancer in future.

Mercks Gardasil adds US indication of genital warts for boys and men: On 16th October 2009,

Gardasils US label was extended to include its use in both men and boys aged 926 years of age. The

pivotal trial results showed an efficacy of 90.4% while preventing external genital lesions of HPV types

6/11/16/18. In addition, Merck also planned to extend its vaccine patient assistance program providing free

Gardasil to 1926 year old uninsured males meeting eligibility criteria but unable to afford the vaccine.

Roches Avastin filed for first-line breast cancer in Japan: In October 2009, Roches Japanese

subsidiary, Chugai has filed a Japanese approval for Avastin in the first-line treatment of advanced orrecurrent breast cancer. The filing in first-line breast cancer was supported by an international Phase III trial (first-

line setting), which showed a significant improvement in PFS. This in turn was supported by Japanese Phase II

safety and efficacy data. Approval of the product will expand Avastins purview beyond colon cancer in the

country, becoming growth driving event.

Eisai to file first in-house breast cancer drug in major markets: Eisai is planning to file its in-house

developed chemotherapy drug eribulin for pre-treated breast cancer (advanced or metastatic) in all the

major markets (US, 5EU & Japan) by March 2010. Preliminary results from the key Phase III trial demonstrated a

significant improvement in overall survival, the primary endpoint.

What will be the major growth indications in

the cancer segment over the period 200814?

Which companies were the winners and losers

in the cancer segment in 2008?

How have recent major launches from

companies such as Roche, Sanofi-Aventis,

AstraZeneca, Novartis and Eli Lilly performed?

Which companies will become the key players

in the cancer segment over the period

200814?

Which products will be impacted by generic

competitors over the period 200814?

Which pipeline products will be the growth

drivers of the future?

Which indications are forecast to have the

highest levels of market potential over the

period 200814?

What will the competitive landscape in lung,

breast, colorectal, ovarian, prostate, lymphoma

and pancreatic cancer in 2014?


5/9



Table of Contents

EXECUTIVE SUMMARY

Epidemiology of Cancer

Global Market Analysis

Pipeline Analysis

Competitive Landscape

CHAPTER 1 SCOPE AND

METHODOLOGY

Scope

Methodology

CHAPTER 2 OVERVIEW AND

EPIDEMIOLOGY OF CANCER

INDICATIONS Summary

Introduction

Overview

Cancer risk factors

Lung cancer

- Overview

- Diagnosis, treatment and

management

- Epidemiology- NSCLC

- SCLC

- Forecast epidemiology- NSCLC

- SCLC

Colorectal cancer

- Overview


management

- Epidemiology

- Forecast epidemiology

Breast cancer

- Overview- Diagnosis, treatment and

management

- Epidemiology


Ovarian cancer

- Overview


management

- Epidemiology


Uterine and cervical cancer

- Overview


management- Epidemiology


Leukemia

- Overview


management

- Epidemiology


Prostate cancer

- Overview

- Diagnosis, treatment andmanagement

- Epidemiology


Pancreatic cancer

- Overview


management

- Epidemiology


Lymphomas

- Overview- Diagnosis, treatment and

management

- Epidemiology


Head and neck cancer

- Overview


management

- Epidemiology


CHAPTER 3 GLOBAL MARKET

ANALYSIS

Summary

Introduction

Market analysis by country

Market analysis by drug class

Leading brand dynamics

- MabThera (rituximab)

Roche/Genentech

- Avastin (bevacizumab)

Roche/Genentech

- Herceptin (trastuzumab)

Roche/Genentech/Chugai

- Glivec/Gleevec (imatinib)

Novartis- Taxotere (docetaxel) Sanofi-

Aventis

Leading brands by type of cancer

Key recent events in the cancer

market

- FDA approves Cervarix for

cervical cancer

- Merck's Gardasil adds US

indication of genital warts for

boys and men

- Roche's Avastin is filed for first-line breast cancer in Japan

- Eisai to file first in-house breast

cancer drug in major markets

- Novartis's Tasigna bolsters its

CML franchise

Antineoplastics

- Competitive dynamics of

antineoplastics

- Leading brands of

antineoplastics

- Antineoplastic mAb marketanalysis- Market dynamics

- Key brands analysis

- Antineoplastic protein kinase

inhibitors- Market dynamics


- Vinca alkaloid market analysis- Market dynamics


- Anti-metabolites- Market dynamics


- Platinum compounds- Market dynamics


- Antineoplastic sales forecast

Cytostatic hormonal therapies

- Competitive dynamics of

cytostatic hormonal therapies

- Leading brands of cytostatic

hormonal therapies

- Cytostatic gonad hormone

analog market analysis


6/9



Table of Contents

- Market dynamics


- Aromatase inhibitors- Market dynamics


- Anti-androgens- Market dynamics

- Key brand analysis

- Cytostatic hormonal therapy

sales forecast

- Global cancer market sales

forecast

CHAPTER 4 PIPELINE ANALYSIS

Summary

Introduction

Key trends in R&D

- Targeted therapies are changing

the treatment regimen of cancer

- Biomarkers are personalizing

oncology treatment

- Cancer vaccines enhance the

body's immune response

- Pricing is becoming a major

issue for cancer patients

- Combination treatments are

becoming the treatment ofchoice

Leading drugs in development

- Phase III and pending approval

compounds- Enzastaurin Eli Lilly

- BiovaxID Biovest International

and Accentia Biopharmaceuticals

- Recentin (cediranib) AstraZeneca

- Zactima (vandetanib)

AstraZeneca

- Axitinib (AG-13736) Pfizer

- Provenge (sipuleucel-T) Dendreon

- Recently approved/marketed

drugs- Arzerra (ofatumumab)

GSK/Genmab

- Afinitor (everolimus) Novartis

- Iressa (gefitinib) AstraZeneca

- Tykerb/Tyverb (lapatinib) GSK

- Votrient (pazopanib) GSK

Pipeline forecast of key compounds

- Factors affecting forecasts

CHAPTER 5 COMPETITIVE

LANDSCAPE

Summary

Introduction

- Sales performance of leading

players

Roche

- Sales focus by drug class

- Regional sales distribution

- Marketed product portfolio

- Pipeline analysis

- Strategic and growth analysis- Drivers of growth

- Resistors of growth

SanofiAventis- Sales focus by drug class



- Pipeline analysis



AstraZeneca



- Marketed product portfolio- Pipeline analysis



Novartis




- Pipeline analysis



Eli Lilly




- Pipeline analysis



Pfizer




- Pipeline analysis



Takeda




- Pipeline analysis



Bristol-Myers Squibb




- Pipeline analysis



CHAPTER 6 APPENDIX

IMS Data

- Antineoplastic and

immunomodulating agents- L1: Antineoplastics

- L2: Cytostatic hormone therapy

- Forecast factors

- Glossary- Abbreviations used in this report

- Index

LIST OF FIGURES

Types of breast cancers

Types of leukemia

Chemotherapy options forHodgkin's disease

Head and neck cancers and their

risk factors

Worldwide cancer market share by

region, 2008

Current pharmacological treatment

options for cancer

Key drugs in late-stage

development or that have been

recently launched


7/9



Table of Contents

Contribution of the top 10 players

to growth of the global cancer

market, 200708

Roche's cancer sales by drug class,2008

SanofiAventis's cancer sales by

drug class, 2008

AstraZeneca's cancer sales by drug

class, 2008

Novartis's cancer sales by drug

class, 2008

Pfizer's cancer sales by drug class,

2008

Takeda's cancer sales by drug class,

2008 BMS' cancer sales by drug class,

2008

LIST OF TABLES

Estimated prevalence of NSCLC

across seven major markets, 2008

Estimated prevalence of SCLC


Forecast epidemiology of NSCLC

across seven major markets,

200814

Forecast epidemiology of SCLC


200814

Estimated prevalence of colorectal

cancer across seven major markets,

2008

Forecast epidemiology of colorectal


200814

Estimated prevalence of breast


2008

Forecast epidemiology of breast


200814

Estimated prevalence of ovarian


2008

Forecast epidemiology of ovarian


200814

Estimated prevalence of uterine and

cervical cancer across seven major

markets, 2008

Forecast epidemiology of uterineand cervical cancer across seven

major markets, 200814

Estimated prevalence of leukemia


Forecast epidemiology of leukemia


200814

Estimated prevalence of prostate


2008

Forecast epidemiology of prostatecancer across seven major markets,

200814

Estimated prevalence of pancreatic


2008

Forecast epidemiology of

pancreatic cancer across seven

major markets, 200814

Estimated prevalence of lymphomas


Forecast epidemiology oflymphomas across seven major

markets, 200814

Estimated prevalence of head and

neck cancer across seven major

markets, 2008

Forecast epidemiology of head and

neck cancer across seven major

markets, 200814

Global cancer market by geography,

2008

Breakdown of the global cancermarket by drug class, 2008

Leading brands in the global cancer

market, 2008

Leading brands in breast cancer,

2008

Leading brands in colon cancer,

2008

Leading brands in prostate cancer,

2008

Leading brands in lung cancer, 2008

Breakdown of the global

antineoplastic market by drug class,

2008

Leading brands in globalantineoplastics market, 2008

Chronology of new indication

approvals for Eloxatine

Antineoplastic sales forecast,

200814

Breakdown of the global cytostatic

hormonal therapies by drug class,

2008

Leading brands in global cytostatic

hormonal therapies market, 2008

Cytostatic hormonal therapy salesforecast, 200814

Global cancer market sales forecast,

200814

An overview of enzastaurin

An overview of BiovaxID

An overview of Recentin

The Horizon Study Program

An overview of Zactima

Overview of Zactimas Phase III

development plan

An overview of axitinib

An overview of Provenge

An overview of Arzerra

An overview of Afinitor

An overview of Iressa

An overview of Tykerb/Tyverb

An overview of Votrient

Key pipeline and recently approved

products sales forecast, 200814

Leading players in the global cancer

market, 200814 Regional sales distribution of Roche,

2008

Roche's cancer product portfolio,

2008

Roche's cancer R&D product

pipeline, October 2009

Regional sales distribution of Sanofi-

Aventis, 2008

SanofiAventis's cancer product

portfolio, 2008


8/9



Table of Contents

Sanofi-Aventis's cancer R&D

product pipeline, October 2009

Regional sales distribution of

AstraZeneca, 2008 AstraZeneca's cancer product

portfolio, 2008

AstraZeneca's cancer R&D product



Novartis, 2008

Novartis' cancer product portfolio,

2008

Novartis's cancer R&D product


Regional sales distribution of Eli

Lilly, 2008

Eli Lilly's cancer product portfolio,

2008

Eli Lilly's cancer R&D product


Regional sales distribution of Pfizer,

2008

Pfizer's cancer product portfolio,

2008

Pfizer's cancer R&D product



Takeda, 2008

Takeda's cancer product portfolio,

2008

Takeda's cancer R&D product


Regional sales distribution of BMS,

2008

BMS' cancer product portfolio, 2008

BMS' cancer R&D product pipeline,October 2009


9/9

+44 (0) 207 900 6688FAX BACK TO:

Company details

3

Company name: ________________________________________________________

EU companies (except UK) must supply VAT / BTW / MOMS / MWST / IVA / FPA number:

_____________________________________________________________________________________________

Purchase Order Number (if required)_____________________________________

Recipient details (If different from Payor)

Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS)

First Name: Last Name:

Email

Job Title

Department

Address

City State/Province

Country Post Code/ZIP

Tel Fax

Payment method

Please indicate your preferred currency: GB EUR US$Total order value is ____________________________

I will forward a check payable to Business Insights Limited.

Please invoice my company (please complete invoice address below)

I would like to pay by bank transfer (email address required)

Debit my credit/charge card: Amex Visa Mastercard

Card No________________________________________________________________________

Expiry Date _________ / _________ Signature ______________________________

4

Sign here to confirm your order:

ORDERS WITHOUT A SIGNATURE CANNOT BE PROCESSED

Title: Mr/Mrs/Ms (Please use BLOCK CAPITALS)

First Name: Last Name:

Email

Job Title

Department

Address

City State/Province

Country Post Code/ZIP

Tel

Fax

Payor details 5

or scan and e-mail to

[email protected]

Interactive VersionA new, innovative way to view our publications

Customize, search, translate, contrast,

manipulate and extract report content.

- Add 50/75/$95per report

Hard CopyPlease fill out recipient derails below if you wish

to order a printed version of your report(s).

- Add 50/75/$95per report- Please allow 28 days for delivery

I would like to order the following report(s)...1

1.____________________________________________________

2.____________________________________________________

3.____________________________________________________

Ordering Multiple reports:

Email/Fax/Postal promotion

Brochure

Table of Contents

Colleague Recommendation

Trade Press

My Account Manager

Conference materials

Website/web search

Communications FeedbackPlease let us know if any of the following factors influenced your purchase...

(Please use BLOCK CAPITALS)

2

1 report ___________________________

2 reports - save 15% ___________________________3 reports - save 20% ___________________________

Multiple report discounts

1. Price is for a Single User licence

2. Discount applied to sum of total list price. Cannot be used in conjunction with other offers.

3. Contact [email protected] for more information on regional/global licence s

Enter total price below

About Business Insights

Business Insights appreciate the importance of accurate, up-to-date incisive

market and company analysis and our aim therefore is to provide a single,

off-the-shelf, objective source of data, analysis and market insight.

www.globalbusinessinsights.com

breast cancer market1

Documents